Read

Global health update: Nov. 18, 2026

By
Learn more about Hannah Johnson.
Hannah Johnson
Deputy Director, Global Policy
George W. Bush Institute

As we approach World AIDS Day on Dec. 1, the George W. Bush Institute has released a three-part series, Imagining a world without PEPFAR, examining what the world might look like if the United States had not acted against the HIV/AIDS pandemic in 2003. On Dec. 1, the Bush Institute will also welcome journalist and author John Donnelly to Dallas to discuss his new book, Lifeline: The Story of PEPFAR, the Greatest Humanitarian Initiative of Our Time.

Before the President’s Emergency Plan for AIDS Relief (PEPFAR), only about 50,000 of the 4.1 million people living with HIV in sub-Saharan Africa who needed lifesaving antiretroviral treatment had access to it. Today, PEPFAR has saved 26 million lives, helped nearly 8 million babies be born HIV-free, and strengthened economies and societies around the world. The series explores how American leadership, compassion, and bipartisan commitment changed the course of the pandemic and saved lives.

As the U.S. transitions toward greater country ownership through the America First Global Health Strategy, our leaders must keep compassion and accountability at the forefront.

Bush Institute Insights

The George W. Bush Institute has released the final two chapters of Imagining a world without PEPFAR, exploring the program’s far-reaching impact and the importance of sustaining its legacy.

In “Stabilizing societies and saving millions of lives,” we examine the impact of PEPFAR beyond HIV prevention and treatment. Before the program began, HIV/AIDS was devastating families, leaving millions of children without parents and countries without essential workers. Through expanded access to treatment, PEPFAR helped protect families, support economic growth, and reduce social conflict. As the figure below shows, life expectancy increased by as much as 18 years between 2000 and 2021 in countries with longstanding PEPFAR partnerships.

 

 

The third chapter, “Sustaining the commitment,” highlights the people behind these results, including Mohamad Kalyesubula, who recovered from advanced HIV/AIDS after receiving lifesaving treatment and traveled to the White House in 2008 to thank the American people. His story is one of 26 million lives saved through PEPFAR.

 

In 2008, Mohamad personally thanked the people of the United States. Mohamad sadly passed away in 2020, but his story and strength continue to inspire people today. (White House photo by Joyce N. Boghosian)

America First Global Health Strategy Updates

The Nov. 3 midterm elections have set the stage for new congressional leadership and renewed attention to U.S. global health policy. For more than two decades, bipartisan support and congressional oversight have helped ensure the success of programs like PEPFAR. As the America First Global Health Strategy moves toward implementation, Congress has an important role in maintaining transparency, monitoring health outcomes, and ensuring accountability for U.S. investments.

The following resources offer perspectives on what the incoming Congress could mean for U.S. global health programs and partnerships:

  • KFF outlines how Congress could use its oversight, appropriations, and legislative authority to influence global health programming, with a focus on funding transparency, country-led transitions, and measurable results.
  • NPR and The Africa Report examine how changes in congressional leadership could shape U.S. global health engagement, including greater oversight of bilateral health agreements.
  • Devex explores how the new Congress could influence foreign assistance priorities, development funding, and oversight of the administration’s global health strategy.
  • Think Global Health asks four Council on Foreign Relations experts what the election means for global health, highlighting expectations for greater scrutiny of bilateral agreements while noting that funding and structural changes are unlikely to reverse in the near term.
  • On his Substack, Jirair Ratevosian profiles 28 incoming members of Congress who have expressed views on global health and foreign assistance, offering insight into the range of perspectives that could shape future funding and oversight.
  • The New York Times examines concerns from public health experts that separate bilateral agreements could limit coordination against infectious disease outbreaks and weaken global pandemic preparedness.

Figure of the Week

120

That’s how many low- and middle-income countries are covered by an agreement to provide a lower-cost generic version of twice-yearly injectable lenacapavir for HIV prevention. The U.S. Food and Drug Administration granted tentative approval to Dr. Reddy’s Laboratories for the first generic version of the drug, bringing the promising HIV prevention option closer to wider availability. Unitaid and its partners previously secured a price of about $40 per person annually, with initial generic supplies expected before the end of 2026 and broader availability in 2027.

The milestone comes as demand continues to outpace supply in parts of Africa. Rwanda also plans to begin offering lenacapavir at 12 health centers on World AIDS Day, joining Kenya and Uganda in expanding access to this new HIV prevention tool.

The Lasting Impact of America’s Global Health Legacy

Tuberculosis (TB) remains one of the world’s leading infectious disease threats, particularly for people living with HIV, who are about 14 times more likely to develop TB because of weakened immune systems. According to the World Health Organization, 87% of new TB cases in 2024 occurred in 30 high-burden countries. The Global Fund to Fight AIDS, Tuberculosis, and Malaria and its partners have spent years integrating TB services with HIV care and broader health programs to expand access to treatment and strengthen health systems. In 2025, countries supported by the Global Fund treated 7.4 million people for TB, demonstrating the impact of sustained investment and coordinated care.

The latest addition to the Bush Institute’s The Lasting Impact of America’s Global Health Legacy highlights Ani Herna Sari, a TB survivor whose story puts a human face on these efforts. Ani was diagnosed with drug-resistant TB while pregnant and gave birth in isolation. She survived the disease and now advocates for others facing TB. Her experience demonstrates how sustained global health partnerships can transform lives and give people the opportunity to support their communities.

 

 

In the News

  • The Global Fund Board has approved the Malaria Impact Accelerator, a new financing mechanism to bring additional private philanthropic investment into country-led malaria prevention and treatment. The initiative will focus on countries with the highest malaria burden and the least economic capacity, while retaining the Fund’s requirements for country ownership, community engagement, transparency, and oversight. The Board also approved a $325 million operating budget for 2027 to support the next grant cycle and the Global Fund’s efforts to expand access to lifesaving tools and strengthen country-led health programs.
  • The Global Fund and World Bank Group signed an agreement allowing countries to use World Bank financing to purchase quality-assured health products through wambo.org, the Fund’s pooled procurement platform. Pooling orders can help countries secure lower prices and more reliable supplies as they take on a greater share of health costs. Center for Global Development researchers find that directing more health investment through the World Bank’s International Development Association (IDA) could help reach the poorest countries. In 2023, IDA directed nearly 48% of its country-allocable health aid to low-income countries, compared with about 36% across all aid channels.
  • A Brookings analysis finds that in 2025, the U.S. directed about one-third of its foreign aid to or through multilateral organizations. The analysis highlights how institutions such as the Global Fund and Gavi can combine purchasing power to lower the cost of health products. It also recommends an evidence-based review of U.S. multilateral assistance, assessing results, accountability, value for money, and alignment with U.S. priorities.
  • As of Nov. 4, the Ebola outbreak that began in the Democratic Republic of the Congo has caused more than 10,500 confirmed cases and 5,130 deaths, with cases also reported in Kenya and Nigeria, The Economist reports. Conflict, limited testing, and gaps in contact tracing are making containment difficult. Meanwhile, experts convened by the World Health Organization have recommended adding two vaccine candidates specifically designed for the Bundibugyo virus to the ongoing Ebola vaccine trial.
  • The State Department plans to redirect up to $125 million in foreign investment to address energy costs, including $48.5 million Congress appropriated for family planning and reproductive health care in low-income countries, The New York Times reports. A spokesperson for Senate Appropriations Committee Chair Susan Collins opposed the move and urged that “these funds should be allocated as Congress intended.”
  • China has proposed expanding export controls to include technologies used to develop advanced medicines, according to The New York Times. The measures are part of the country’s effort to strengthen its leverage in international disputes. Governments in Europe, Japan, and elsewhere are already seeking to rebuild their capacity to produce antibiotics and pharmaceutical ingredients.
  • The Pan American Health Organization has presented a 2026-2030 malaria elimination plan that aims to reduce malaria incidence in the Americas by 50% from 2024 levels. The plan prioritizes rapid testing, community-based diagnosis and treatment, and sustained domestic financing, particularly in Indigenous communities, mining areas, and remote locations. Separately, in September, Reps. Ami Bera and María Elvira Salazar reintroduced the End Tuberculosis Now Act of 2026. The bipartisan bill would expand access to prevention and care, accelerate research, and require annual reporting on U.S. global TB programs.